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The current CoVid-19 crisis is revealing the strengths and the weaknesses of the world’s 
capacity to respond to a global health crisis. A critical weakness has resulted from the 
excessive centralization of the current biomanufacturing capacities, a matter of great 
concern, if not a source of nationalistic tensions. On the positive side, scientific data and 
information have been shared at an unprecedented speed fuelled by the preprint 
phenomena, and this has considerably strengthened our ability to develop new technology-
based solutions. In this work, we explore how, in a context of rapid exchange of scientific 
information, plant biofactories can serve as a rapid and easily adaptable solution for local 
manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, 
we tested our ability to produce, in the framework of an academic lab and in a matter of 
weeks, milligram amounts of six different recombinant monoclonal antibodies against 
SARS-CoV-2  in Nicotiana benthamiana. For the design of the antibodies, we  took 
advantage, among other data sources, of the DNA sequence information made rapidly 
available by other groups in preprint publications. mAbs were engineered as single-chain 
fragments fused to a human gamma Fc and transiently expressed using a viral vector. In 
parallel, we also produced the recombinant SARS-CoV-2 N protein and the receptor 
binding domain (RBD) of the Spike protein in planta and used them to test the binding 
specificity of the recombinant mAbs. Finally, for two of the antibodies, we assayed a simple 
scale-up production protocol based on the extraction of apoplastic fluid. Our results 
indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in 
little more than 6 weeks in repurposed greenhouses with little infrastructure requirements 
using N. benthamiana as production platform. Similar procedures could be easily deployed 
to produce diagnostic reagents and, eventually, could be  adapted for rapid 
therapeutic responses.
Keywords: COVID-19, SARS-CoV-2, Nicotiana benthamiana, plant-made antibody, plant-made antigen, 
biofactories, molecular farming
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INTRODUCTION
The current pandemic is evidencing several weaknesses in our 
ability to respond to a global crisis, one of which is the 
insufficient and heavily centralized distribution of the world 
manufacturing capacity of bioproducts such as antibodies, 
vaccines, and other biological reagents, especially proteins. Since 
it is economically impracticable to ensure readiness by 
maintaining inactive infrastructures during large periods of 
normality, the development of dual-use systems has been 
proposed, which would serve regular production needs in 
normal times but could be  rapidly repurposed to strategic 
manufacturing requirements in times of crisis. Ideally, such 
adaptable infrastructures should be  widespread to serve local 
demand in case of emergency.
Recombinant protein production in plants is a technologically 
mature bioengineering discipline, with most current plant-based 
bioproduction platforms making use of non-food crops, mainly 
the Nicotiana species tabacum and Nicotiana benthamiana as 
biomanufacturing chassis (Moon et  al., 2019; Capell et  al., 
2020). N. benthamiana is most frequently used in association 
with Agrobacterium-mediated transient expression, also known 
as agroinfiltration, a technology that dramatically reduces the 
time required for product development. Briefly, agroinfiltration 
consists in the massive delivery of an Agrobacterium suspension 
culture to the intercellular space of plant leaves, either by 
pressure, using a syringe (small-scale), or applying vacuum to 
plants whose aerial parts have been submerged in a diluted 
Agrobacterium culture (large-scale). Agrobacterium transfers its 
T-DNA to the cell nucleus, therefore, massively reprograming 
the plant cell machinery toward the synthesis of the T-DNA-
encoded protein(s)-of-interest. Transient expression of the 
transgene is often assisted by self-replicating deconstructed 
virus vectors that amplify the transgene dose, thus boosting 
protein production by several orders of magnitude (Gleba et al., 
2004). Other systems, such as the pEAQ system, rely on viral 
genetic elements for boosting expression without recurring to 
viral replication (Sainsbury et  al., 2009). Transient expression 
in N. benthamiana has become the standard in plant-based 
recombinant protein production due to a unique combination 
of advantages, with speed and high yield as the most obvious 
ones. Maximum production levels in the g/Kg fresh weight 
(FW) range for certain highly stable proteins such as antibodies 
have been reported (Marillonnet et al., 2005). Regarding speed, 
the in-planta incubation times required to obtain maximum 
yield of recombinant protein are no more than 2  weeks.
An important, often insufficiently highlighted feature of 
N. benthamiana transient expression is its relatively small 
infrastructure requirements, partially overlapping with those 
employed in more conventional, medium/high-tech indoors 
agriculture, such as hydroponics, vertical farming, etc. (Buyel, 
2019). In this context, when confronted with the CoVid-19 
crisis, we  decided to exercise a partial reorientation of the 
activities in our academic lab, which is equipped with a 
multipurpose glass greenhouse facility, toward the production 
of SARS-CoV-2 antigens and antibodies against the virus. Here, 
we  describe the recombinant production, purification, and 
analysis of six anti-SARS-CoV-2 monoclonal antibodies at 
laboratory scale, plus a pilot upscaling of two of those six 
antibodies. Next to production scale, a critical parameter to 
assess was the response time. The process described here started 
in mid-April 2020 with the selection of literature-available 
antibody variable sequences and finalized 9  weeks later with 
approximately 0.2 g of anti-SARS-CoV-2 antibody (Ab) produced 
in modular batches of 56 N. benthamiana plants and formulated 
as 1  L of Ab-enriched plant apoplastic fluid. Based on this 
experience, we  estimate that the same process can be  reduced 
up to 6–7  weeks with small pre-adaptations, a remarkably 
short-reaction time for a de novo antibody production system. 
Absolutely key for this fast reaction is the immediate availability 
of scientific data including antibody sequences in pre-print 
repositories. This is, in our opinion, one of the most positive 
lessons that can be extracted from the CoVid-19 crisis. We discuss 
here the possible applications of the fast plant-produced antigens 
and antibodies in diagnostics and therapy and propose the 
repurpose of high-tech agricultural facilities as an alternative 
for decentralized biomanufacturing in times of crisis.
MATERIALS AND METHODS
Plant Material and Growth Conditions
Both N. benthamiana wild type plants and 1,2-xylosyltransferase/
alpha1,3-fucosyltransferase (ΔXT/FT) RNAi knock down lines 
(Strasser et  al., 2008) were grown in the greenhouse. Growing 
conditions were 24°C (light)/20°C (darkness) with a 16-h-light/8-
h-dark photoperiod.
Cloning of Anti-SARS-CoV-2 Antibodies 
and SARS-CoV-2 Antigens
All sequences were cloned and assembled using the GoldenBraid 
(GB) assembly system1 (Sarrion-Perdigones et al., 2013). Antibody 
sequences were obtained from literature (see Table  1). All 
antibodies were cloned as single chain antibodies fused to the 
human IgG1 Fc domain. Those antibodies derived from synthetic 
or camelid single domain VHH libraries (sybody 3, sybody 17, 
and nanobody 72) were designed as direct fusions. CR3009, 
CR3018, and CR3022 human monoclonal antibodies were 
redesigned as single chain variable fragment (ScFv) by connecting 
the variable light (VL) and heavy (VH) chains with a 
GGGGSGGGGSGGGGSSGGGS peptide linker. Antibody 
sequences were codon optimized for N. benthamiana with the 
IDT optimization tool at http://eu.idtdna.com/CodonOpt. Here, 
the optimization is based on the frequencies of each codon 
usage for each organism. In this direction, the tool algorithm 
eliminates codons with less than 10% frequency and re-normalizes 
the remaining frequencies to 100%. Moreover, it reduces 
complexities that can interfere with manufacturing and downstream 
expression, such as repeats, hairpins, and extreme GC content.
The SARS-CoV-2 antigen sequences used (N protein, 
YP_009724397.2; and S-protein RBD domain, YP_009724390.1, 
1 https://gbcloning.upv.es
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aa 319-541) derive from the Wuhan strain NC_045512. Four 
different versions of RBD were designed corresponding to (i) 
the native sequence with a C-terminal 6xHis-Tag (nRBD:His) 
or (ii) an N-terminal 6xHis-Tag and a C-terminal KDEL sequence 
for ER retention (His:nRBD:KDEL), and (iii and iv) their 
corresponding N. benthamiana codon optimized counterparts 
(bRBD:His and His:bRBD:KDEL), using the same tool as above. 
For N protein, a 6xHis tag was fused to the N-terminus of 
an N. benthamiana codon optimized sequence (His:bN).
DNA sequences were domesticated as level 0 phytobricks 
for GB cloning and ordered for synthesis as double-stranded 
DNA fragments (gBlocks, Integrated DNA Technologies). gBlocks 
were first cloned into the domestication vector pUPD2 (Vazquez-
Vilar et  al., 2017) in a BsmBI Golden Gate restriction/ligation 
reaction [37°C – 10  min, 50x (37°C – 3  min/16°C – 4  min), 
50°C – 10  min, 80°C – 10  min]. The ligation product was 
transformed into E. coli Top  10 electrocompetent cells and 
positive clones were verified by restriction digestion analysis 
and sequencing. pUPD2 level 0 phytobricks were then cloned 
into the expression vectors pGreen SP-hIgG1 (antibody sequences), 
pCambiaV1 (RBD sequences), or pCambiaV2 (N sequences). 
pGreen SP-hIgG1 is a pGreen vector-based adaptation of the 
MagnICON® 3' provector pICH7410 (ICON Genetics; Giritch 
et  al., 2006) that is designed for BsaI cloning of GB (B4-B5) 
standard parts as in-frame fusions with the tobacco (1–3)-beta-
glucanase signal peptide and the human IgG1 Fc domain. 
Similarly, pCambiaV1 and pCambiaV2 are pCambia based 
adaptations of the MagnICON® 3' provector pICH7410 that 
are designed for BsaI cloning of GB standard parts as in-frame 
fusions with tobacco (1–3)-beta-glucanase signal peptide 
(pCambiaV1, for expression of secreted proteins) or without 
any subcellular localization signal (pCambiaV2, for expression 
of cytoplasmic proteins). Assembly reactions were performed 
as above, and the ligation reactions were transformed into 
E. coli Top 10 electrocompetent cells. Positive clones were verified 
by restriction digestion analysis. All level 0 parts and expression 
vectors used in this work are listed in Supplementary Table  1.
Transient Expression in Nicotiana 
benthamiana
For transient expression in N. benthamiana, the plasmids were 
transformed into Agrobacterium tumefaciens strain GV3101 C58C1 
by electroporation. The same strain but carrying the pSoup 
helper plasmid was employed to allow the replication of the 
pGreen vectors, which encode the antibodies. Overnight grown 
exponential cultures were collected by centrifugation and the 
bacterial pellets were resuspended in agroinfiltration solution 
(10  mM MES, 20  mM MgCl2, 200  μM acetosyringone, pH 
5.6) and incubated for 2  h at RT in a horizontal rolling mixer. 
For small-scale agroinfiltration, culture optical density at 600 nm 
was adjusted to 0.1 with agroinfiltration solution and the bacterial 
suspensions harboring the 3' antibody or antigen modules, the 
Integrase (pICH14011), and the 5' module (pICH17388) were 
mixed in equal volumes. Negative control samples were 
agroinfiltrated with pICH11599_DsRed and Integrase module. 
Agroinfiltration of 5–6-week-old N. benthamiana plants was 
carried out through the abaxial leaf surface using a 1 ml needle-
free syringe (Becton Dickinson S.A.). For pilot-scale production, 
the bacterial suspensions were prepared as above except that 
a lower OD600 was used (0.005 for sybody17 agroinfiltration 
and 0.01 for nanobody72 agroinfiltration). Additionally, for 
sybody17 agroinfiltration, a bacterial suspension of pICH11599_
DsRed, a MagnICON® 3'module encoding the fluorescent protein 
DsRed, was added to the final Agrobacterium infiltration solution 
in a ratio 1:1:0.9:0.1 (pICH17388:pICH14011:pGreenSP-Sybody17-
hIgG1:pICH11599_DsRed). Delivery of Agrobacterium to the 
plant cells was carried out by vacuum infiltration in a vacuum 
degassing chamber (model DP118, Applied Vacuum Engineering) 
provided with a 30  L infiltration tank. The aerial part of whole 
plants (seven plants at a time) was immersed into the 
Agrobacterium infiltration solution; vacuum was applied for 
1 min at a vacuum pressure of 0.8 bar and then slowly released.
Apoplast Fluid Extraction
Fourteen days post-vacuum agroinfiltration leaves were excised 
and then infiltrated with 20  mM phosphate buffer (7.4  mM 
NaH2PO4, 12.6 mM Na2HPO4.7H2O, pH 7), without (sybody17) 
or with (nanobody72) 0.5 mM PMSF (Sigma-Aldrich, #78830), 
following the same procedure as the vacuum agroinfiltration. 
After eliminating the buffer excess with tissue paper, the leaves 
were introduced into mesh zipped bags and then centrifuged 
at 2800  rpm for 5  min (twice) using a portable cloth dryer 
(Orbegozo SC4500). Thus, the apoplastic fluid was obtained 
from the drain tube. The apoplastic fluid was centrifuged 
(10  min, 11,000 x g, at 4°C) to remove any cell debris and 
Agrobacterium, the supernatant was collected and then four 
fractions of 4  ml were concentrated eight times using 10  kDa 
Amicon Ultra-4 10K Centrifugal filters (Millipore) after 
centrifugation (20  min, 3,700 x g, at 4°C). The concentration 
of proteins in the apoplastic fluid was quantified using the 
TABLE 1 | Detailed information of six different antibodies selected for recombinant expression in plants.
Name Type Size (with SP) Target Neutralizing activity References
CR3022 ScFv-Fc IgG1 (VL-Linker-VH) 56.2 kDa RBD (SARS-CoV and 
SARS-CoV-2)
No Tian et al., 2020
sybody3 VHH-Fc IgG1 42.4 kDa RBD (SARS-CoV-2) Unknown Walter et al., 2020
sybody17 VHH-Fc IgG1 42.2 kDa RBD (SARS-CoV-2) Unknown Walter et al., 2020
nanobody72 VHH-Fc IgG1 43.3 kDa RBD (SARS-CoV and 
SARS-CoV-2)
Yes Wrapp et al., 2020
CR3009 ScFv-Fc IgG1 (VH-Linker-VL) 55.5 kDa Protein N (SARS-CoV) Unknown van den Brink et al., 2005
CR3018 ScFv-Fc IgG1 (VH-Linker-VL) 54.9 kDa Protein N (SARS-CoV) Unknown van den Brink et al., 2005
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Bio-Rad Protein Assay following the manufacturer’s instructions 
and using BSA for standard curve preparation. The concentration 
of intact antibodies was estimated by densitometry of Coomassie 
stained-gel using the software ImageJ. For this, the peak area 
corresponding to the full-size antibody band was integrated, 
and its abundance in relation with the remaining bands 
was estimated.
Antibody Extraction and Purification
The N. benthamiana leaves infiltrated with the different anti-
SARS-CoV-2 recombinant antibodies were collected 7  days 
post infiltration (dpi). Leaves were frozen in liquid nitrogen 
and stored at −80°C until used. Protein crude extracts were 
obtained by homogenizing ground frozen leaf tissue with cold 
PBS buffer (20 mM NaH2PO4, 80 mM Na2HPO4.7H2O, 100 mM 
NaCl, pH 7.4) in a 1:3 (w/v) and were centrifuged at 13,000 rpm 
for 15  min at 4°C. For antibody purification, 4  g of ground 
agroinfiltrated tissue were extracted in 12  ml of cold 20  mM 
phosphate buffer. Samples were centrifuged at 10,000 x g for 
15  min and the supernatant was transferred to a clean tube 
and further clarified by filtration through a 0.22 μm membrane 
filter. The recombinant antibodies were purified by affinity 
chromatography with Protein A agarose resin (ABT Technology) 
following a gravity-flow procedure according to the manufacturer’s 
instructions. Hundred millimolar citrate buffer pH 3 was used 
for elution and 1 M Tris-HCl pH 9 was used for neutralization 
of the eluted sample (37.5  μl for each 250  μl elution fraction). 
Purified antibody preparations were quantified using the Bio-Rad 
Protein Assay following the manufacturer’s instructions and 
using BSA for standard curve preparation. The concentration 
of intact antibody was estimated by densitometry as described 
in the previous section.
Antigen Extraction and Purification
The N. benthamiana leaves infiltrated with the different SARS-
CoV-2 proteins were collected 5 (RBD) or 7 (N protein)  dpi. 
Leaves were frozen in liquid nitrogen and stored at −80°C 
until used. Protein extraction was performed using 3–6  g of 
ground frozen tissue in 1:3 (w/v) extraction buffer. Three 
different buffers were tested as a first approach in order to 
optimize the purification yields. Buffer A: PBS buffer with 
10  mM imidazole, pH 8. Buffer B: Buffer A supplemented 
with 1% Triton X-100, and Buffer C: Buffer B supplemented 
with 20% glycerol, 10% sucrose, and 0.05% 2-β-mercaptoethanol. 
Samples were vigorously vortexed and centrifuged at 10,000 
x g for 15 min at 4°C. The supernatant was carefully transferred 
to a clean tube and filtered through a 0.22  μm syringe filter. 
Protein purification was carried out by Ni-NTA affinity 
chromatography as described in (Fernandez-del-Carmen et  al., 
2013). Purified proteins were quantified using the Bio-Rad 
Protein Assay following the manufacturer’s instructions and 
using BSA for standard curve preparation.
SDS-PAGE and Western Blot Analysis
Proteins were separated by SDS-PAGE electrophoresis on 
NuPAGE 10% Bis-Tris Gels (Invitrogen) using MES-SDS running 
buffer (50  mM MES, 50  mM Tris-base, 3.5  mM SDS, 1  mM 
EDTA, pH 7.3) under reducing conditions. Gels were visualized 
by Coomassie blue staining. For Western blot analysis, proteins 
were transferred to PVDF membranes (Amersham Hybond™-P, 
GE Healthcare) by semi-wet blotting (XCell II™ Blot Module, 
Invitrogen, Life Technologies) following the manufacturer’s 
instructions. Blots were blocked with 2% ECL Prime blocking 
agent (GE Healthcare) in PBS-T [PBS buffer supplemented 
with 0.1% (v/v) Tween-20]. For anti-SARS-CoV-2 antibody 
detection, the blots were incubated with 1:20,000 HRP-conjugated 
rabbit anti-human IgG (Sigma-Aldrich, #A8792). For SARS-
CoV-2 antigen detection, the blots were incubated with 1:2,000 
Anti-His mouse monoclonal primary antibody (Qiagen, #34660) 
and then incubated with 1:10,000 peroxidase labeled anti-mouse 
IgG secondary antibody (GE Healthcare). Blots were developed 
with ECL Prime Western blotting Detection Reagent (GE 
Healthcare) and visualized using a Fujifilm LAS-3000 imager.
Antigen ELISA
The overnight coating of Costar 96 Well EIA/RIA plates (Corning) 
was carried out at 4°C with 100 μl of 4 μg/ml RBD (RayBiotech, 
#230-30162), His:bN or BSA (used as control) in Coating buffer 
(15  mM Na2CO3, 35  mM NaHCO3, pH 9.6). After four washes 
with 300  μl of PBS, the plate was blocked with 200  μl of a 2% 
(w/v) ECL Advance Blocking Reagent (GE Healthcare) solution 
in PBS-T [PBS supplemented with 0.1% (v/v) Tween-20] for 
2  h at RT. The plate was washed four times with PBS, and 
then starting at 2  μg of the purified antibody preparation per 
well, or 1  μg of the full-size antibody from apoplastic fluid per 
well (both 100  μl), 1:5 serial dilutions in blocking solution were 
incubated for 1  h 30  min at RT. After four washing steps with 
PBS-T (PBS buffer supplemented with 0.05% Tween-20), 1:2,000 
HRP-labeled rabbit anti-human IgG (Sigma-Aldrich, #A8792) 
in blocking solution was added. After 1 h, the plate was washed 
with PBS and the substrate o-phenylenediamine dihydrochloride 
SIGMAFAST™ OPD tablet (Sigma-Aldrich, #P9187) was added 
(following manufacturer’s instructions). Reactions were stopped 
with 50  μl 3  M HCl per well and absorbance was measured 
at 492  nm. The endpoint dilution titer was determined as the 
last concentration of each purified antibody showing an absorbance 
value higher than the value defined as cutoff (mean blank +3SD). 
Blank is defined as the values from each ELISA test against 
BSA (Zrein et  al., 1986; Armbruster and Pry, 2008).
Sandwich ELISA
The sandwich ELISAs were performed as described in the 
antigen ELISA section with a few changes. The plates were 
coated with 100  μl of 4  μg/ml murine anti-His mAb (Qiagen, 
#34660), and after blocking, the plates were incubated with 
100  μl of the crude extracts of the (nRBD:His/His:bN) antigen 
expressing leaves. WT crude extracts were used as negative 
control. The crude extracts were prepared by adding 1:3 (w/v) 
PBS buffer and then were subjected to sonication. The extract 
was centrifuged (13,000  rpm, 4°C, and 15  min) and the 
supernatant was used in the incubation step. The antigens were 
sandwiched with 1  μg of the corresponding purified antibody 
preparation (100  μl in blocking solution) per well (1  h 30  min 
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incubation, RT). The same procedure as in the antigen ELISA 
was followed for the incubation with the conjugated secondary 
antibody, colorimetric reaction, and measurement.
RESULTS
Cloning and Expression of Anti-SARS-
CoV-2 Recombinant Antibodies
Six different antibody sequences were selected for recombinant 
production in N. benthamiana, following a plant deconstructed 
viral strategy based on Magnifection technology as described 
earlier (Marillonnet et  al., 2005; see Table  1). Four of those 
were directed against the receptor binding domain (RBD) of 
the SARS-CoV-2 spike (S) protein, whereas the remaining 
two were directed against the N protein. All six antibodies 
were engineered as single polypeptide chains fused to the 
human Cɣ2-Cɣ3 constant immunoglobulin domains. Three of 
them, those derived from single chain camelid or synthetic 
VHH antibody libraries, were produced as direct fusions. The 
other three, derived from full-size human monoclonal antibodies, 
were redesigned as scFvs, using a linker peptide that connects 
VH and VL regions (see Figure 1A). The nucleotide sequences 
of the different variable regions were obtained from the 
literature, then chemically synthesized with appropriate 
extensions and cloned into a destination Magnifection-adapted 
vector using a type IIS restriction enzyme strategy. The cloning 
cassette was flanked by a β-endoglucanase signal peptide for 
apoplastic localization in N-terminal and the human Cɣ2-Cɣ3 
domains of the human IgG1  in the C-terminal side. The 
resulting vectors were transferred to Agrobacterium cultures 
and agroinfiltrated in N. benthamiana leaves in combination 
with a 5' MagnICON® module, containing the RNA polymerase 
and movement protein, and with an integrase module 
(Figure  1B). For antibody production, we  used wild-type and 
RNAi ΔXT/FT glycoengineered N. benthamiana plant lines, 
the latter with a downregulation of plant-specific xylose and 
fucose glycosylation (Strasser et  al., 2008). Infiltrated leaves 
were examined daily, and only minimal damage was observed 
in the agroinfiltrated tissues during the incubation period. 
After 7  days, leaf samples were collected, ground, and crude 
extracts were analyzed in SDS-PAGE under reducing conditions. 
As can be observed in Figures 2A,B (upper panel), all samples 
produced Coomassie-detectable bands of the expected antibody 
A
B
FIGURE 1 | Design for the expression of anti-SARS-CoV-2 recombinant antibodies. (A) Schematic representations of VHH-Fc and ScFv-Fc antibody versions. 
VHH, heavy chain only single domain antibody; ScFv, single chain variable fragment; Fc, human IgG1 Cɣ2-Cɣ3 domains. (B) Schematic representation of the 
cloning procedure for transient expression via MagnICON®. VHHs and ScFvs cloning into the pGreen SP-hIgG1 vector and coinfiltration together with the plasmids 
pICH17388 and pICH14011 for the in planta viral reconstruction (through ΦC31 mediated PB recombination) and antibody expression. AttB & AttP, site-specific 
recombination site; SP, signal peptide; NTR, nontranslated region; tNOS, terminator of nopaline synthase; pAct2, actine2 promoter of Arabidopsis thaliana; RdRP, 
RNA-dependent RNA polymerase; MP, viral movement protein; pHsp81 promoter of the heat shock protein 81.
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A B
C D
FIGURE 2 | Analysis of the expression of all six anti-SARS-CoV-2 recombinant antibodies produced in N. benthamiana leaves. Coomassie stained SDS gels (upper 
panel) and Western blots (down panel) of protein extracts from wild-type (A) and ΔXT/FT (B) N. benthamiana leaves agrotransformed all of them with six antibodies. 
Seventeen microliter of crude extract was loaded per well in SDS gels. The blots were incubated with an antibody against constant region of human IgG. (C,D) 
Coomassie stained SDS gels with purified (P) recombinant antibodies from ΔXT/FT plants compared to their corresponding protein crude extract (C.E) for each 
analyzed antibody. Twenty microgram of total protein from crude extract per well and 3 μg of purified protein per well were loaded in SDS gels. Control samples (−) 
were agroinfiltrated with Integrase module and pICH11599_DsRed vectors only, as indicated in section Materials and Methods. Arrows indicate the presence and 
position of the corresponding band protein for each antibody.
size. scFv-IgG1 55–56  kDa antibodies migrated slightly above 
the 50–55  kDa Rubisco large subunit, partially masking its 
detection. VHH-Fc antibodies migrated at the expected 
42–43  kDa size. The identity of the Coomassie bands was 
confirmed by Western blot using an anti-human IgG1 antibody 
for detection (Figures  2A,B, lower panel). As shown in 
Figures  2A,B, under reducing conditions lower molecular 
weight (MW) bands were also detected, probably as a result 
of partial proteolytic degradation. Small-scale affinity purification 
was carried out for all six antibodies produced in ΔXT/FT 
plants using protein A affinity chromatography (Figures 2C,D). 
The concentration of affinity-purified antibody preparations 
was used to estimate the yield of the final product, which 
ranged between 73.06  μg/g FW (CR3022 antibody) to 
192.63 μg/g FW (nanobody72 antibody) at most (see Table 2). 
The percentage of the full-size antibody with respect to the 
total antibody preparation including cleavage fragments is also 
shown in Table  2.
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Cloning and Expression of SARS-CoV-2 
Recombinant Antigens
The in-planta production of SARS-CoV-2 RBD and N protein 
antigens was also assayed in parallel using a similar strategy 
as described for antibody production. For this purpose, two 
versions of the expression vector were designed for RBD, one 
with the native viral sequence and the other with an 
N. benthamiana codon-optimized sequence. For the N protein, 
only the N. benthamiana codon-optimized sequence was 
employed. For RBD, native and codon optimized versions were 
targeted to the secretory pathway with the tobacco glucan 
endo-1,3-beta-glucosidase signal peptide (SP:nRBD:His and 
SP:bRBD:His) and versions containing a KDEL peptide for 
ER retention (SP:His:nRBD:KDEL and SP:His:bRBD:KDEL) 
were also generated. All nucleotide sequences were chemically 
synthesized with a small nucleotide extension coding for a 
histidine tag for detection (Figure  3A).
As described for antibody production, MagnICON®-derived 
3' vector modules encoding RBD and N proteins were 
agroinfiltrated in combination with an integrase module and 
a 5'-module lacking any additional subcellular localization 
signal. Shorter incubation times were decided in antigen 
production as compared to antibodies because antigen 
constructs produced different degrees of necrotic lesions in 
the leaves, ranging from mild symptoms in N protein to 
severe necrosis after 4 days in native RBD. For those constructs 
producing more severe lesions, incubation time was reduced 
to 5 days, and for the rest the incubation period was extended 
to 7  days. RBD:His from SP:nRBD:His and SP:bRBD:His 
expressing leaves was extracted and purified using small-
scale affinity-chromatography with Ni-NTA columns and 
the resulting Coomassie and a Western blot analysis, under 
reducing conditions, are shown in Figure  3B. RBD:His can 
be  detected as an estimated 30  kDa band with the presence 
of higher MW bands that suggest multimerization and an 
18  kDa band probably corresponding to a degradation 
product. ER retention did not improve expression levels of 
RBD for the native version, nor for the N. benthamiana 
optimized one (data not shown). Addition of 1% Triton 
TABLE 2 | Yield estimation for all six purified recombinant antibodies, RBD and 
N proteins.
Purified protein Yield (μg/g FW) % Full-size Ab % TSP
CR3022 73.06 5.07 1.96
sybody3 122.53 56.57 2.56
sybody17 153.36 83.91 3.31
nanobody72 192.63 75.95 3.18
CR3009 73.38 83.97 1.88
CR3018 81.24 90.19 1.79
nRBD:His (Buffer A) 4.31 ND 0.18
nRBD:His (Buffer B) 4.02 ND 0.051
bRBD:His (Buffer A) 2.94 ND 0.097
bRBD:His (Buffer B) 5.21 ND 0.051




FIGURE 3 | SARS-CoV-2 RBD and N proteins expression in N. benthamiana agroinfiltrated leaves. (A) Schematic representation of the pUPD2 and 3' module 
vectors generated for antigen production. (B) Coomassie stained SDS-PAGE (left) and Western blot (right) of crude extracts from non-infiltrated N. benthamiana 
leaves (Control), leaves infiltrated with viral vectors for the expression of nRBD:His (n stands for native sequence), His:bN and bRBD:His (b stands for N. 
benthamiana codon optimized sequence) and the corresponding purified proteins.
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X-100 to the standard extraction buffer (see Materials and 
Methods) did not improve the yield, which was estimated 
as 2–4  μg/g FW (Table  2). N protein was extracted from 
agroinfiltrated leaves and affinity purified following the same 
procedure described for RBD. A major 49  kDa band was 
detected both on the crude extract and upon purification 
(Figure 3B). Small-scale affinity-chromatography with Ni-NTA 
columns gave an estimated yield of 30  μg/g FW for N 
protein (Table  2).
Characterization of Antigen-Antibody 
Binding Activities
Binding activities of affinity purified anti-RBD and anti-N 
antibodies were analyzed by antigen ELISA as shown in 
Figures  4A,B. As expected, all assayed antibodies were active 
in binding their respective antigen. Endpoint dilution titers of 
antibody preparations were calculated for anti-RBD and anti-N 
antibodies using the commercial RBD antigen and our purified 
His:bN antigen. Sybodies 3 and 17 and nanobody72, and CR3009 
showed high dilution titers, (0.75, 0.03, 0.03, and 0.58  μM, 
respectively), but the performance of CR3022 and CR3018 was 
significantly lower (2.85 and 2.91 μM, respectively). In a parallel 
experiment, we  tested the ability of plant-made antibodies to 
selectively detect our own plant-made antigens, including here 
also the N protein, using a sandwich ELISA approach. For 
this analysis, ELISA plates were coated with a murine anti-His 
mAb, incubated with crude plant extracts from antigen-producing 
plants and sandwiched with purified plant-made antibodies. 
As shown in Figure  4C, all antigen-producing plant extracts 
gave sandwich-ELISA signals significantly above the background 
when assayed using their cognate antibodies, thus evidencing 
the capacity of both, antibodies and antigens, to function as 
potent diagnostic tools. Background signals in this experiment 
are likely due to cross-reaction of the anti-human IgG secondary 
antibody with the murine anti-His mAb, and could be  easily 
reduced for more potent diagnostic applications by employing 
recombinant antibody formats other than IgG.
Pilot Antibody Upscaling and Analysis of 
Apoplastic Fluid
In the design of a pilot upscaling experiment, we  favored 
modularity and tried to maximize the affordability and 
adaptability of the process by reducing the requirements for 
highly specialized lab equipment. We  carried out a final 
agroinfiltration for recombinant antibody production using a 
total of 112 plants, equivalent to approximately 2.5  kg of fresh 
plant material. The plants were divided in two batches of 56 
plants each and used to produce sybody17 and nanobody72 
respectively, as these antibodies showed the most promising 
binding activities and yields. To facilitate the upscaling of the 
agroinfiltration process, plant seedlings were transplanted in 
growth modules, each module comprising seven pots kept 
together in a double layer of disposable plastic-board hexagons 
as shown in Figure  5A. Each production batch consisted in 
eight hexagonal modules. When plants were 6  weeks old, they 
were agroinfiltrated by submerging each hexagon upside down 
into a 40  cm diameter cylindrical tank filled with 30  L of an 
Agrobacterium suspension, set inside a cylindrical vacuum degas 
chamber (Figure  5A). In this way, seven plants at a time were 
vacuum-agroinfiltrated by slowly releasing vacuum while leaves 
remained submerged in the solution. Next, plants were rinsed, 
brought back to the growth chamber and incubated for 14 days 
before harvest. Two different concentrations of the Agrobacterium 
suspension were used in this experiment. One of them 
(sybody17) consisted in an OD600 0.005 final mix containing 




FIGURE 4 | Comparison of binding activities of anti-SARS-CoV-2 purified 
antibodies by ELISA tests. (A,B) Antigen ELISA titers graph of anti-RBD (A) or 
anti-N (B) purified antibody preparations. Binding activities were calculated by 
absorbance measurements at 492 nm. The X axis indicates the amount (μg) 
of antibody preparation per well. Solid lines indicate the ELISA test against 
RBD commercial or our purified His:bN protein, and dashed lines indicate the 
corresponding control ELISA tests against BSA. Bars represent mean ± SD, 
n = 3 independent replicates. (C) Sandwich ELISA plots obtained using anti-
RBD and anti-N purified antibody preparations (1 μg per well). Plates were 
coated with commercial anti_His monoclonal antibody, incubated with crude 
extracts of plant-made antigens (nRBD:His or His:bN, respectively), and 
developed with the different plant-made antibody preparations as indicated. 
Wild type crude extracts samples were used as negative control. Bars 
represent mean ± SD, n = 3 independent replicates.
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pICH11599_DsRed at 1:1:0.9:0.1 ratio, where pICH11599_DsRed 
is a MagnICON® 3'module encoding DsRed. The fluorescent 
marker was added to the infiltration mix to monitor the 
extension of the viral infection foci. As described elsewhere 
(Julve et  al., 2013; Julve Parreño et  al., 2018) superinfection 
exclusion among virial clones yields mosaic-like expression 
patterns of individual clones, therefore the tiles produced by 
red fluorescent proteins were used as an indication of the 
extension and distribution of the unlabeled foci producing the 
recombinant antibody. In parallel, nanobody72 up-scaled 
production was undertaken by agroinfiltration of an OD600 
0.01 Agrobacterium culture mix containing pICH14011, 
pICH17388, and pGreenNanobody72-IgG1 at 1:1:1 ratio. After 
14  days, DsRed tiles in sybody17 experiment, clearly visible 
with the naked eye, finalized their expansion in most 
agroinfiltrated leaves, an indicator that the expression tiles had 
covered the whole leaf surface (Figure 5B). At this stage, leaves 
were harvested and submitted to an apoplastic fluid recovery 
assay, where >0.5  kg batches of detached leaves were vacuum-
infiltrated in 20  mM phosphate buffer using the same vacuum 
device as described above. Once rinsed to remove the excess 
of buffer, leaves were packed in mesh zipped bags, spinned 
down in a spin portable cloth dryer, and the intercellular 
apoplastic fluid was recovered from the drain tube. With this 
simple procedure, between 940 and 1,200  ml of apoplastic 
fluid (sybody 17 and nanobody 72, respectively) was recovered 
from 1.2  kg of detached leaves. A fraction of the apoplastic 





FIGURE 5 | Analysis of upscaling production of anti-RBD sybody17 and nanobody72 antibodies as an example for a pilot assay. (A) Hexagon growth modules 
used in the pilot assay with N. benthamiana plants and vacuum degas chamber used for vacuum agroinfiltration. (B) Different agroinfiltrated ΔXT/FT N. benthamiana 
leaves with DsRed tiles as indicator of the extension of the recombinant protein production. (C) Coomassie stained SDS gel and Western blot of protein extracts 
from ΔXT/FT plants expressing sybody17. (D) Coomassie stained SDS gel of protein extracts from WT plants expressing nanobody72. Total crude extract (C.E), 
purified extract (P), total apoplastic fluid (A) and concentrated apoplastic fluid (C.A). Wild type crude extracts (control) and apoplastic fluid with (+) or without (−) 
DsRed expression were used as control samples. Seventeen microliter of total protein extract per well and 3 μg of purified protein per well were loaded in SDS gels. 
Arrows show the position of each full-size antibody band. (E) Antigen ELISA titers graph of full-size antibody from apoplastic fluid of sybody17 and nanobody72-
expressing plants. Binding activities were calculated by absorbance measurements at 492 nm. The X axis shows the amount (μg) of antibody per well. Solid lines 
indicate the ELISA test against commercial RBD, and dashed lines indicate the corresponding control ELISA tests against BSA. Bars represent mean ± SD, n = 3 
independent replicates.
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centrifugal filters (<10 kDa), and the rest was kept refrigerated 
for further analysis. Figures 5C,D show the Coomassie-staining 
and Western blot analysis, under reducing conditions, of crude 
extracts as well as apoplastic fluid preparations, and their 
corresponding purifications. Crude extracts in this pilot 
experiment showed a VHH-IgG1 band similar in intensity to 
that obtained in small-scale experiments (data not shown). 
Interestingly, apoplastic fluid consisted in a very simplified 
mix of proteins, with the recombinant antibody being among 
the most predominant ones. As shown, the different optical 
density of the Agrobacterium culture, together with the presence 
of a competing DsRed clone, clearly influenced the accumulation 
levels, with the yields of nanobody72 clearly outperforming 
those of its sybody counterpart. Unfortunately, the antibodies 
seemed partially degraded as indicated by the presence of two 
bands smaller than the expected VHH-Cɣ2-Cɣ3 size, which 
could be  compatible with degradation fragments. Degradation 
was only partially solved with the addition of the protease 
inhibitor PMSF into the recovered phosphate buffer, as shown 
with nanobody72 production (Figure 5D). Despite degradation, 
in a densitometric analysis, we  estimate that the recovered 
apoplastic fluid in this assay contained 159  mg per liter of 
intact mAb full-size (152  μg/g FW). Finally, we  analyzed by 
antigen ELISA the binding activities of intact sybody17 and 
nanobody72 antibodies obtained from apoplastic fluid 
(Figure  5E). The high dilution titers observed (0.38  μM for 
sybody17 and 0.37  μM for nanobody72) showed that this 
simple antibody preparation can be directly employed in detection 
procedures without the need of additional purification steps.
DISCUSSION
Several N. benthamiana-dedicated bioproduction facilities are 
functioning worldwide, as those from Leaf Expression Systems 
in United  Kingdom (Dobon, 2019), Icon Genetics (Giritch 
et  al., 2006) and Fraunhofer in Germany (Wirz et  al., 2012), 
iBio facility (Holtz et  al., 2015) or Kentucky Bioprocessing in 
United  States (Olinger et  al., 2012), among others. Notably, 
Medicago recently announced the building a new 44,000  sqm 
facility with capacity for around 40–50 million of planned 
doses of flu vaccine per year. Such facilities usually involve 
separated modules for upstream processing, namely a wet-lab 
module for preparation of the bacterial inoculum, a regular 
plant growth chamber, and agroinfiltration room, and a post-
infiltration growth chamber. In addition, downstream processing 
facilities are often situated next or to the production ones to 
minimize the handling time of fresh tissues. Whereas installed 
capacity of plant-dedicated biofactories is in continue growth, 
they are clearly insufficient to respond to global or even regional 
demands in times of crisis. We  reasoned that, at least for 
upstream processes, the infrastructures required for medium-
scale N. benthamiana-based production are not radically different 
to those employed in high-tech agriculture practices as 
hydroponics, aeroponics, or vertical farming, and thus high-
tech agriculture facilities could be  easily repurposed as 
biomanufacturing facilities in a matter of days or weeks 
(McDonald and Holtz, 2020). Also, the use of alternative plants 
and expression systems, in addition to N. benthamiana, could 
offer additional flexibility and speed. Interestingly in this context, 
plant-based platforms have important advantages in comparison 
to the use of more traditional production systems, especially 
in the case of diagnostic reagents in which the required 
production scale and the final purity are different from 
therapeutics. As an exercise to practically test the repurposing 
requirements, we  describe here the partial adaptation of our 
research laboratory and greenhouse facilities to the production 
of SARS-CoV-2-related antigens and antibodies using 
N. benthamiana agroinfiltration as manufacturing platform.
In Figure 6, we show a chronogram of the activities undertaken 
by our team toward the production of SARS-CoV-2 antigens 
and antibodies, from the initial selection of the nucleotide 
sequences of the genes-of-interest to the production of 1  L 
of plant apoplastic fluid of recombinant sybody17 and 
nanobody72. In our hands, the whole process took a total of 
9  weeks with non-exclusive personnel dedication and partially 
restricted access to our facilities. The process can be  divided 
in three periods: the first step (DESIGN), taking approximately 
10  days, was dedicated to construct design and gene synthesis. 
It was pivotal in this step to have open access to viral and 
antibody sequences deposited in pre-print repositories. 
Particularly remarkable was the openness of academic labs 
that immediately released primary sequence information of 
partially characterized anti-SARS-CoV-2 monoclonal antibodies, 
an exercise that should serve as an example in the future. 
Due to our limited testing capacity, the number of parallel 
designs per product was maintained relatively low, and several 
design decisions (e.g. codon optimization and purification tags) 
were taken based in a best-guess approach. Ideally, proper 
crisis preparedness should involve a centralized automated 
equipment such as a biofoundry (Hillson et  al., 2019), with 
which the design space could be extended dramatically without 
causing delay. The second phase (BUILD) was dedicated to 
cloning and construct building and lasted less than 3  weeks. 
Adapted plasmids and cloning procedures from previous projects 
are available in our lab (Sarrion-Perdigones et al., 2011; Vazquez-
Vilar et  al., 2017), therefore no significant time lag occurred 
in this step. Importantly, this period also involved seeding a 
new plant batch at the scale required for pilot production in 
week seven (112 plants distributed in 16 hexagonal modules 
in this case). In a third phase (TEST), starting on week 5, 
all constructs were infiltrated at a small scale (three replicate 
leaves each), shortly incubated (5 or 7  days) and then tested 
functionally in parallel analyses. This small-scale assay took 
two additional weeks, summing a total of approximately 50 days 
for the complete process. Synthetic Biology-inspired Design-
Build-Test (DBT) cycles are conceived as iterative processes. 
Here, we  present it as a conceptual framework as no iterations 
are shown in this work. New DBT cycles can be  run fuelled 
by the conclusion of previous cycles to generate new optimized 
versions of the product. Based on this experience, we  estimate 
that the whole DBT cycle could be  shortened to 30  days or 
less by optimizing the pipeline (e.g. introducing centralized, 
automatized design and build phases), and by improving 
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preparation and anticipation in the facilities (Figure  6). For 
instance, note that moving from step 2 to step 3 without delay 
requires a small batch of plants be  always maintained in the 
facility, as it was in our case to supply our research requirements. 
This only involves transplanting 10–15 seedlings every 3 weeks, 
and then disposing of them every other 3  weeks once they 
start flowering. If a continuous plant supply is not maintained, 
a minimum of three extra weeks needs to be  considered to 
have plants ready for the first TEST iteration.
Whereas the first version of products shown here lack 
iterative optimization, it would serve eventually to respond to 
the most urgent demands. In our case, as the results of the 
first DBT process arose, the best performing version (V1.0) 
of two of the products were taken to PRODUCTION phase. 
In the exercise shown here, the upscaling was relatively small 
(112 plants, approximately 2.5  kg FW). Post-agroinfiltration 
incubation time was extended to 14  days to maximize yields. 
In the meantime, optimization of the purification/extraction 
methods were undertaken at small scale, so that the new 
knowledge acquired could be  applied in the batch purification 
of the pilot experiment. In a crisis-scenario, and given the 
modularity of the proposed scheme, several medium-size 
production modules can be  replicated in a farming facility 
and reproduced in several farms, allowing easy scalability. 
Successive iterations with small-scale agroinfiltration could 
be an effective way to maximize yields and reduce development 
times by comparing different small-scale strategies. It should 
be  mentioned that the basic apoplast-based downstream 
processing proposed here could only be used, with the necessary 
adaptations, in a limited number of crisis-related applications, 
mainly related with detection and diagnosis. Other uses, certainly 
therapeutic ones, would involve additional regulatory 
considerations including GMP downstream facilities, which are 
beyond the scope of this exercise.
As a result of this experience, several improvements can 
be  envisioned. We  employed the MagnICON® vector system 
with few adaptations for all the attempted proteins. Although 
MagnICON® produces maximum yields for many products, 
some proteins, particularly viral antigens may express better 
with other (e.g., non-viral) systems. In our experiments, antigens 
showed rather low expression levels despite optimization attempts 
using codon optimization and different localization signals. In 
adapting to an emergency, it would be  advisable to perform 
initial expression tests using different production platforms also 
involving non-replicative methods (Sainsbury and Lomonossoff, 
2008) or DNA viruses (Diamos and Mason, 2018; Yamamoto 
et  al., 2018; Diamos et  al., 2020) and to incorporate them to 
the initial optimization test. As mentioned, this could be  done 
in a centralized manner, later distributing expression clones 
to several repurposed production facilities. In contrast to 
FIGURE 6 | Schematic view of the Design-Build-Test and Production pipelines employed in this work. The upper timeline represents the actual timespan of the 
experiments. Note that the time points represent approximately the days required to produce and initially characterize the designated products; notwithstanding, 
some of the results shown in previous figures correspond to extended analysis obtained at a later stage, during the preparation of this manuscript. The lower 
timeline describes the estimated minimal timespan that would result by introducing some of the optimizations described in the text.
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antigens, recombinant single-chain antibodies showed in general 
higher and more uniform expression levels, as could be expected 
from their more similar structure. We  chose to adapt full 
human IgGs to a scFv-IgG1 format to facilitate cloning and 
expression procedures, since it has been earlier described in 
plants that single chain formats reproduce the binding activities 
of the original full-size antibodies from which they derive. 
Whereas full-size antibodies are likely more marketable for 
therapeutic uses, they require co-expression of heavy and light 
chains using non-interfering replicons, or the employ of 
non-replicative systems, which undergo chain shuffling and 
therefore are not suitable for the expression of antibody cocktails. 
We  chose the single-chain antibody production first because 
this strategy facilitates the upstream process, making use of 
a single viral vector. Secondly, because our final goal is to 
produce antibody cocktails as described earlier (Julve Parreño 
et  al., 2018), and this technology is currently optimized for 
single-chain antibody formats. Furthermore, the single chain 
format facilitated the comparisons with VHH antibodies, also 
produced as IgG1 fusions.
The plant-made SARS-CoV-2 products described here have 
several potential applications in the diagnosis area. Both RBD 
and N proteins can be  used as reagents for serological assays 
(Amanat et  al., 2020; Liu et  al., 2020), although further yield 
optimizations should be  required. For those assays, where 
antigen glycosylation is an important factor, glycoengineered 
plants (Strasser et al., 2008) can provide a competitive alternative 
to mammalian cells cultures (O’Flaherty et al., 2020). Regarding 
antibodies, they can serve as internal references for the 
quantification of serological responses. With small modifications, 
the same antibodies can be  adapted for sandwich ELISA and 
employed in the detection and quantification of antigens or 
viral particles (e.g., using sandwich antibody pairs detecting 
different surface epitopes), a better proxy for infectiveness than 
RNA. We also show here that apoplastic fluid is an inexpensive 
antibody preparation suitable for certain applications that require 
low-cost preparations, e.g., the concentration of the virus from 
environmental samples. In terms of yields, the recovery of 
affinity-purified nanobody72 extracted from whole tissue 
(192 μg/g FW at most) is in the same range that the estimated 
concentration of the same antibody in the apoplastic fluid 
(approximately 160 μg/ml, equivalent to 152 μg/g FW at most). 
Therefore, we  can conclude that in our hands recovery rates 
from intercellular fluid are similar to those obtained in affinity 
purified preparations. As shown here, the protein complexity 
in the apoplast is greatly reduced compared to whole extracts, 
therefore the apoplast could be  regarded as a plant-equivalent 
of hybridoma supernatant or ascited fluid, although at much 
lower cost. Unfortunately, apoplastic preparations as well as 
whole tissue extracts are prone to partial antibody degradation 
probably due to endogenous proteases. It has been suggested 
that the length of CDR H3 could influence antibody stability, 
however in the case of the scFv-Fc reported here, CDR H3 
lengths do not seem to be  a major factor affecting proteolytic 
degradation (12 amino acids in CR3022, 14 amino acids in 
CR3009; Puchol Tarazona et  al., 2020). As earlier reported, 
proteolytic degradation can be  minimized using extraction 
buffers with appropriate protease inhibitors, as it was shown 
for nanobody72, or downregulating protease activity (Niemer 
et  al., 2014). Other possibilities to solve degradation problems 
are to determine and redesign the cleavage sites, or ultimately 
to separate degradation bands during downstream processing 
via gel filtration or similar size exclusion technologies.
The current pandemic crisis has evidenced the power of 
new antibody selection procedures, either based on single-cell 
selection from human peripheral blood mononuclear cells, in 
the case of full-size antibodies, or based on ultra-high throughput 
selection of synthetic libraries (sybodies) in the case of camelid-
derived nanobodies (Zimmermann et  al., 2018; Walter et  al., 
2020). Large collections of anti-SARS-CoV-2 potentially 
neutralizing antibody sequences were made available to the 
scientific community in a question of weeks rather than months. 
It does not go unnoticed that the combination of rapid antibody 
selection procedures with fast, modular and scalable plant 
expression also has implications in the therapeutic arena as 
an ideal system for passive immunization. Intravenous polyclonal 
immunoglobulins (IVIG) from recovered patients have been 
shown a very effective CoVid-19 treatment in several studies 
(Montelongo-Jauregui et  al., 2020, and references herein); 
however, the limited availability of patient sera hampers its 
application in practice. Interestingly, we  showed in a recent 
work that large recombinant polyclonal antibody cocktails 
(pluribodies), mimicking a mammalian immune response can 
be  produced in N. benthamiana with high batch-to-batch 
reproducibility (Julve Parreño et al., 2018). Passive immunization 
with recombinant antibody cocktails resembles a natural response 
more than a monoclonal therapy, requires shorter developmental 
times and is probably more robust against the development 
of resistances. Additionally, other antibody-based therapeutics, 
such as receptor decoys fused to Fc of IgG1 (such as ACE-Fc 
described recently; Glasgow et  al., 2020), could be  designed 
and produced rapidly in plants followed a similar scheme as 
described here.
In conclusion, based on the results of the exercise described 
here, we  propose the repurposing of indoors farms into plant-
based biomanufacturing facilities as a viable option to respond 
to local and global shortages of bioproducts such as diagnostics 
and therapeutic reagents in times of crisis.
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